Edition:
India

Intervacc AB (IVACC.ST)

IVACC.ST on Stockholm Stock Exchange

40.10SEK
28 Oct 2020
Change (% chg)

-5.70kr (-12.45%)
Prev Close
45.80kr
Open
45.70kr
Day's High
45.70kr
Day's Low
38.85kr
Volume
979,124
Avg. Vol
188,918
52-wk High
58.60kr
52-wk Low
12.40kr

Latest Key Developments (Source: Significant Developments)

Intervacc Expands Distribution Agreement With Animalcare Group
Thursday, 29 Aug 2019 

Aug 29 (Reuters) - Intervacc AB ::SAID ON WEDNESDAY HAS THROUGH UNIT NORDVACC LÄKEMEDEL EXPANDED DISTRIBUTION AGREEMENT WITH ANIMALCARE GROUP UNIT ECUPHAR NV.AGREEMENT GIVES CO EXCLUSIVE RIGHTS TO SELL A PORTFOLIO OF VETERINARY PHARMACEUTICAL PRODUCTS FROM ANIMALCARE GROUP ON SWEDISH MARKET.FIRST TWO PRODUCTS IN AGREEMENT WILL BE INTRODUCED ON SWEDISH ANIMAL HEALTH MARKET DURING CURRENT YEAR.  Full Article

Intervacc Sings Contract With Swedish University Of Agricultural Science
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Intervacc AB ::INTERVACC AND THE SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES, SLU, SIGN A MULTI-YEAR CONTRACT FOR THE DEVELOPMENT OF INNOVATIVE ANIMAL HEALTH VACCINES.CONTRACT IS A CONTINUATION AND EXPANSION OF COLLABORATION BETWEEN SLU, KAROLINSKA INSTITUTET (KI) AND INTERVACC.AGREEMENT INCLUDES CONTINUED DEVELOPMENT OF TWO OTHER VACCINE PROJECTS.WE ARE CONFIDENT THAT STRANGVAC IS JUST FIRST OF A SERIES OF RECOMBINANT BASED VACCINES THAT WILL EMERGE FROM THESE ONGOING COLLABORATIONS - CEO.  Full Article

Intervacc AB Q4 EBITDA Loss At SEK 5.3 Million
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Intervacc AB ::Q4 NET SALES SEK 3.2 MILLION VERSUS SEK 3.1 MILLION YEAR AGO.Q4 EBITDA LOSS SEK 5.3 MILLION VERSUS LOSS SEK 5.5 MILLION YEAR AGO.  Full Article

Intervacc Appoints New CEO
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Intervacc AB ::NEW CEO APPOINTED FOR INTERVACC - A INNOVATIVE AND EXPANDING VACCINE COMPANY.HAS APPOINTED ANDREAS ANDERSSON AS CEO.  Full Article

Intervacc Q3 EBITDA Loss Widens To SEK 4.5 Million
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Intervacc AB ::Q3 NET SALES SEK 11.0 MILLION VERSUS SEK 11.1 MILLION YEAR AGO.Q3 EBITDA LOSS SEK 4.5 MILLION VERSUS LOSS SEK 0.9 MILLION YEAR AGO.  Full Article

BRIEF-Intervacc And Karolinska Institutet Extend Contract

* INTERVACC AND THE KAROLINSKA INSTITUTET EXTEND CONTRACT FOR THE DEVELOPMENT OF INNOVATIVE ANIMAL HEALTH VACCINES